Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rigel ( (RIGL) ) just unveiled an announcement.
On May 11, 2026, Rigel Pharmaceuticals entered into a license agreement with Arvinas and Pfizer to obtain exclusive worldwide rights to develop, manufacture and commercialize VEPPANU (vepdegestrant) and related products, consolidating Rigel’s control over this targeted breast cancer therapy. The deal structure includes a $70 million upfront payment, up to $15 million tied to transition activities, as much as $320 million in potential regulatory and sales milestones, tiered mid-teens to mid-twenties royalties on net sales, and up to $40 million in reimbursed development costs, with Pfizer retaining responsibility for certain ongoing development work while Rigel assumes primary global development and commercialization responsibilities once antitrust clearance under the Hart-Scott-Rodino Act is obtained.
The agreement embeds customary diligence, intellectual property, and termination provisions, and runs on a product- and country-specific basis until expiration of the royalty term, after which Rigel’s license becomes fully paid-up and perpetual. The transaction underscores Rigel’s strategic push into oncology and positions the company as the key commercial driver for VEPPANU worldwide, with potential upside from milestone-driven economics balanced by sizable upfront and development reimbursement commitments, and regulatory timing risk tied to required antitrust review.
The most recent analyst rating on (RIGL) stock is a Buy with a $57.00 price target. To see the full list of analyst forecasts on Rigel stock, see the RIGL Stock Forecast page.
Spark’s Take on RIGL Stock
According to Spark, TipRanks’ AI Analyst, RIGL is a Neutral.
The score is driven primarily by materially improved financial performance (profitability and cash-flow turnaround) and a generally constructive earnings call with reiterated 2026 guidance. These positives are tempered by weak technicals (below key moving averages with negative MACD) and some execution/program risk highlighted by rising costs and the ended Lilly collaboration.
To see Spark’s full report on RIGL stock, click here.
More about Rigel
Rigel Pharmaceuticals is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative therapies, now expanding its portfolio into oncology. The company’s latest move centers on VEPPANU (vepdegestrant), an approved treatment in the United States for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer who have progressed after at least one line of endocrine therapy.
Average Trading Volume: 365,828
Technical Sentiment Signal: Hold
Current Market Cap: $481.8M
Learn more about RIGL stock on TipRanks’ Stock Analysis page.